Barclays
YARW

Barclays’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

Barclays’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$188 – 5504
2024
Q3 		$188 Buy
+2
New +$190 ﹤0.01% 5167
2020
Q3 		– Sell
-35
Closed -$219K – 5614
2020
Q2 		$219K Buy
35
+29
+483% +$196K ﹤0.01% 3996
2020
Q1 		$59K Buy
6
+2
+50% +$31.4K ﹤0.01% 5124
2019
Q4 		$73K Buy
4
+2
+100% +$33.3K ﹤0.01% 5621
2019
Q3 		$35K Sell
2
-1
-33% -$16.1K ﹤0.01% 6062
2019
Q2 		$62K Buy
3
+2
+200% +$49.5K ﹤0.01% 5993
2019
Q1 		$27K Buy
+1
New +$24K ﹤0.01% 6236
2018
Q4 		– Sell
-1
Closed -$22.4K – 6843
2018
Q3 		$37K Buy
+1
New +$30.9K ﹤0.01% 6236
2018
Q2 		– Hold
0
– – – 6710
2018
Q1 		– Hold
0
– – – 5909

Other funds holding YARW

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Barclays's YARW Position: Q4 2024 in Review

Barclays sold out of Yarrow Bioscience, Inc. Common Stock (YARW) in Q4 2024, closing a stake of 2 shares — an estimated $188 sold.

Barclays first reported a position in YARW in Q3 2018 and held it in 8 quarters. The position peaked at $219K in Q2 2020. 34 funds tracked by Wall St. Rank hold YARW as of Q4 2024.

  • Barclays reported no remaining Yarrow Bioscience, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Barclays sold 2 Yarrow Bioscience, Inc. Common Stock shares in Q4 2024, an estimated $188.
  • Barclays first reported a position in Yarrow Bioscience, Inc. Common Stock in Q3 2018 and held it in 8 quarters.
  • Barclays's Yarrow Bioscience, Inc. Common Stock position peaked at $219K in Q2 2020.
  • 34 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q4 2024.

Based on Barclays's 13F filing for Q4 2024, filed 13 Feb 2025.